DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
The listing of references in the PCT international search report is not considered to be an information disclosure statement (IDS) complying with 37 CFR 1.98. 37 CFR 1.98(a)(2) requires a legible copy of: (1) each foreign patent; (2) each publication or that portion which caused it to be listed; (3) for each cited pending U.S. application, the application specification including claims, and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion, unless the cited pending U.S. application is stored in the Image File Wrapper (IFW) system; and (4) all other information, or that portion which caused it to be listed. In addition, each IDS must include a list of all patents, publications, applications, or other information submitted for consideration by the Office (see 37 CFR 1.98(a)(1) and (b)), and MPEP § 609.04(a), subsection I. states, “the list ... must be submitted on a separate paper.” Therefore, the references cited in the international search report have not been considered. Applicant is advised that the date of submission of any item of information in the international search report will be the date of submission of the IDS for purposes of determining compliance with the requirements for the IDS with 37 CFR 1.97, including all timing statement requirements of 37 CFR 1.97(e). See MPEP § 609.05(a).
The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.
Claim Objections
Claim 2 and 5 are objected to because of the following informalities: the claims recite “said secretory protein” should be “said recombinant human secretory protein” to be consistent with claim language set forth in claim 1, line 1. Appropriate correction is required.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim(s) 1, 2, 3, 4, 5, 7, 8, 9, 11, 16 and 19 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Gaull (US 6,020,015).
Regarding claim 1, 2, 3, and 4, Gaull discloses synthetic human infant formula (edible composition) (‘015, claim 1) comprising recombinant human milk proteins including secretory immunoglobin-A (IgA), lactoferrin and combination thereof (‘015, col. 6, ln. 61-67, claim 1).
Regarding claim 5 and 19, Gaull discloses the recombinant human milk proteins including secretory lactoferrin comprising hybrid N-glycans (‘015, col. 4, ln. 32-43).
Regarding claim 7, 8, and 9, Gaull discloses the synthetic human infant formula simulates the composition of fresh human milk (‘015, col. 2, ln. 27-30) which includes so called classical nutrients including lipids, vitamins and minerals (‘015, col. 5, ln. 58-59).
Regarding claim 11, Gaull discloses the synthetic human infant formula comprising human milk protein including alpha-casein (isolated protein) (‘015, col. 6, ln. 61-67, claim 1).
Regarding claim 16, Gaull discloses synthetic human infant formula (edible composition) (‘015, claim 1) comprising recombinant human milk proteins from human cells (mammal) (‘015, col. 6, ln. 61-67).
Claim(s) 1-19 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by De Oliveira Afonso (US 2024/0138463).
Regarding claim 1, 2, 3, 4, 11, De Oliveira Afonso discloses infant formula (edible composition) comprising recombinant human milk protein, casein (protein) and whey protein-lipid concentrate (‘463, [0014]). With respect to claim 3 and 4, De Oliveira Afonso discloses the recombinant human milk protein including immunoglobulins (IgA), lactoferrin) (‘463, [0023]).
Regarding claim 5, 6, and 19, De Oliveira Afonso discloses infant formula (edible composition) comprising glycans and human milk oligosaccharides include 2′-FL (2′-Fucosyllactose) and lacto-N-neotetrose (LNnT) (or mixture thereof) (‘463, [0053], [0054]).
Regarding claim 7, 8, 9, 13 and 14, De Oliveira Afonso discloses infant formula (edible composition) comprising lipids (‘463, [0031]), minerals and vitamins (‘463, [0020], [0058]). With respect to claim 13, calcium ([0068]). With respect to claim 14, vitamin A ([0068]).
Regarding claim 10, De Oliveira Afonso discloses infant formula (edible composition) comprising nucleotides (‘463, [0065], [0069, [0072]).
Regarding claim 12, De Oliveira Afonso discloses infant formula (edible composition) comprising oils including coconut oil, sunflower oil, high oleic safflower oil (‘463, [0056]).
Regarding claim 15, De Oliveira Afonso discloses infant formula (edible composition) comprising probiotics and prebiotics (‘463, [0020]).
Regarding claim 16, 17 and 18, De Oliveira Afonso discloses infant formula (edible composition) comprising recombinant human milk protein is from yeast cells, Saccharomyces cerevisiae (‘463, [0021]).
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claim(s) 20 is rejected under 35 U.S.C. 103 as being unpatentable over by De Oliveira Afonso (US 2024/0138463).
Regarding claim 20, De Oliveira Afonso discloses the claimed invention as discussed in claim 1. De Oliveira Afonso discloses the human recombinant, lactoferrin in and about of 0.1 g to about 3 g in 100g of the formula (‘463, claim 44) which corresponds to a range of about 0.1% to 3% by weight, which overlaps the cited range. In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990).
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to HONG THI YOO whose telephone number is (571)270-7093. The examiner can normally be reached M-F, 7AM to 3PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, ERIK KASHNIKOW can be reached at (571)270-3475. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/HONG T YOO/ Primary Examiner, Art Unit 1792